Method for improving biological activity of anti-CD43 monoclonal antibody

A monoclonal antibody and biologically active technology, applied in the field of biopharmaceuticals, can solve the problems of poor chemotherapy selectivity, not widely used, and large side effects, and achieve the effects of simple operation, good therapeutic effect and low cost.

Inactive Publication Date: 2019-05-28
SHENYANG SUNSHINE PHARMA +1
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, traditional chemotherapy has poor selectivity and side effects; induction therapy is not sensitive to some leukemias; and HSCT is not widely used due to donor and cost constraints and graft-versus-host disease.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for improving biological activity of anti-CD43 monoclonal antibody
  • Method for improving biological activity of anti-CD43 monoclonal antibody
  • Method for improving biological activity of anti-CD43 monoclonal antibody

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] The main purpose of this embodiment is to investigate the effect of different concentrations of Kifunensine on cell growth, so as to obtain the optimal concentration.

[0026] Take an anti-CD43 monoclonal antibody producing cell line (according to the method disclosed in Chinese patent ZL200680020846.5 to prepare anti-CD43 monoclonal antibody and produce it in CHO cells), centrifuge at 1000rpm for 5 minutes, and use Lonza commercial basal culture Based on PowerCHO-2, the precipitate was resuspended into the shake flask, and the viable cell density and viability were measured with a cell counter, and the shake flask was placed in a cell culture shaker to complete cell recovery. Cell subculture and expansion were carried out according to the subculture cycle once every 3 days, and the viable cell density and viability were recorded. After the cell viability reached more than 90% for 3 consecutive times, the cells were inoculated into a 250ml shake flask with an inoculation...

Embodiment 2

[0030] The main purpose of this example is to investigate the effect of different concentrations of Kifunensine on the expression level of anti-CD43 monoclonal antibody during batch culture, so as to optimize the optimal concentration.

[0031]Take an anti-CD43 monoclonal antibody producing cell line (according to the method disclosed in Chinese patent ZL200680020846.5 to prepare anti-CD43 monoclonal antibody and produce it in CHO cells), centrifuge at 1000rpm for 5 minutes, and use Lonza commercial basal culture Based on PowerCHO-2, the precipitate was resuspended into the shake flask, and the viable cell density and viability were measured with a cell counter, and the shake flask was placed in a cell culture shaker to complete cell recovery. Cell subculture and expansion were carried out according to the subculture cycle once every 3 days, and the viable cell density and viability were recorded. After the cell viability reached more than 90% for 3 consecutive times, the cells...

Embodiment 3

[0041] The main purpose of this example is to investigate the effect of Kifunensine on the biological binding activity of anti-CD43 monoclonal antibody.

[0042] Take an anti-CD43 monoclonal antibody producing cell line (according to the method disclosed in Chinese patent ZL200680020846.5 to prepare anti-CD43 monoclonal antibody and produce it in CHO cells), centrifuge at 1000rpm for 5 minutes, and use Lonza commercial basal culture Based on PowerCHO-2, the precipitate was resuspended into the shake flask, and the viable cell density and viability were measured with a cell counter, and the shake flask was placed in a cell culture shaker to complete cell recovery. Cell subculture and expansion were carried out according to the subculture cycle once every 3 days, and the viable cell density and viability were recorded. After the cell viability reached more than 90% for 3 consecutive times, the cells were inoculated into a 250ml shake flask with an inoculation volume of 60ml. The...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a method for improving the biological activity of an anti-CD43 monoclonal antibody. The method comprises the step of adding Kifunensine into the culture process when the monoclonal antibody produces cells. The method provided by the invention can be used for effectively improving the biological activity of the anti-CD43 monoclonal antibody. The operation is simple and convenient; the cost is low; wide industrial application prospects are realized.

Description

technical field [0001] The invention belongs to the field of biopharmaceuticals, and in particular relates to a method for improving the biological activity of an anti-CD43 monoclonal antibody. Background technique [0002] Acute leukemia (AL) is a group of malignant clonal diseases with abnormal proliferation of hematopoietic stem cells. It belongs to hematological malignancies and can occur at any age, but it ranks first among malignant tumors in children and adults under 35 years old, leading to death The rate is higher. There are approximately 2 to 3 million acute leukemia patients in my country, and 30,000 to 40,000 new patients are newly diagnosed every year. Acute leukemia is a systemic malignant tumor. Traditional chemotherapy, induction therapy and hematopoietic stem cell transplantation (hematopoietic stem cell transplantation, HSCT) are the main treatment methods. However, traditional chemotherapy has poor selectivity and side effects; induction therapy is not s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12P21/08C12R1/91
Inventor 王超娄竞苏冬梅靳征刘颖侯绪凤
Owner SHENYANG SUNSHINE PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap